The primary goal of this project is to determine the molecular mechanisms involved in and relevance of proteolytic processing events involved in Alzheimer's Disease (AD). The project will test several hypotheses related to amyloid formation and deposition in AD, since the production of amyloid from the amyloid precursor protein (APP) is a primary and ubiquitous feature of this heterogenous disease. The use of site-directed mutagenesis will (1) define the precise nature of the APP and the low affinity nerve growth factor receptor (NGFR) cleavage sites in neuronal cells and (2) determine if APP mutations that are linked to two human diseases characterized by amyloid deposition actually cause amyloid deposition in transgenic mice (with Core D). Such animals would represent the first animal models of amyloid formation and would be valuable for mechanistic and therapeutic studies. The amyloid A4 protein will be directly expressed in relevant brain regions in transgenic mice to determine the pathologic (with Project 5 and Core D) and behavioral (with Core F) consequences of amyloid formation and deposition. Using protein sequence information provided by Project 3, we will isolate clones that encode proteases that are involved in the processing of APP and the NGFR. The cloned proteases will be overexpressed in a prokaryotic (or eukaryotic, if necessary) system for purification by Project 3. This material will be used for the production of polyclonal antisera, and for structural analysis and inhibitor studies by Project 1. The polyclonal antisera and DNA probes will be used to characterize the proteases in cells and in normal and AD tissue in collaboration with Project 2 and Project 5.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG010481-02
Application #
3790571
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Abbott Laboratories
Department
Type
DUNS #
City
North Chicago
State
IL
Country
United States
Zip Code
60064
Meyer, E M; Tay, E T; Zoltewicz, J A et al. (1998) Neuroprotective and memory-related actions of novel alpha-7 nicotinic agents with different mixed agonist/antagonist properties. J Pharmacol Exp Ther 284:1026-32
Stine Jr, W B; Snyder, S W; Ladror, U S et al. (1996) The nanometer-scale structure of amyloid-beta visualized by atomic force microscopy. J Protein Chem 15:193-203
Bodovitz, S; Klein, W L (1996) Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 271:4436-40
Kohnken, R E; Ladror, U S; Wang, G T et al. (1995) Cathepsin D from Alzheimer's-diseased and normal brains. Exp Neurol 133:105-12
Wang, G T; Ladror, U S; Holzman, T F et al. (1994) Cleavage of fluorogenic substrates for APP-processing proteases by human brain extracts. Ca(2+)-substrate interaction is responsible for Ca2+ stimulation of the neural protease activity. Mol Chem Neuropathol 23:191-9
Ladror, U S; Wang, G T; Klein, W L et al. (1994) Potential beta PP-processing proteinase activities from Alzheimer's and control brain tissues. J Protein Chem 13:357-66
Ladror, U S; Kohnken, R E; Wang, G T et al. (1994) Evidence against a role for the Kunitz domain in amyloidogenic and secretory processing of the amyloid precursor protein. J Neurochem 63:2225-30
Pope, W B; Lambert, M P; Leypold, B et al. (1994) Microtubule-associated protein tau is hyperphosphorylated during mitosis in the human neuroblastoma cell line SH-SY5Y. Exp Neurol 126:185-94
Snyder, S W; Wang, G T; Barrett, L et al. (1994) Complement C1q does not bind monomeric beta-amyloid. Exp Neurol 128:136-42
Ladror, U S; Snyder, S W; Wang, G T et al. (1994) Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-beta by cathepsin D. J Biol Chem 269:18422-8

Showing the most recent 10 out of 12 publications